Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Artec, Inc. (Bulls Board) -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (28)	12/14/2005 2:26:17 PM
From: rmarc	Read Replies (1) \| Respond to of 51

donpat, I don't agree that ATKJ has more near term or long term potential. ADXS is entering phase I/II trials, has 37.6 million shares O/S, $2.3 million in cash, NO litigation issues & a 20 year EXCLUSIVE license for Listeria. Shinn & Knight can't raise ANY money because of their past dealings & bad reputation. I have talked to Knight & I can tell you he is just a figure head, not very bright with no managerial talent. Shinn is even worse. I bought ADXS at about .22 cents & will hold until at least the trial results are determined. If they are positive, ADXS will explode as it is very under valued now.